This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Collaboration streamlines patient access to oncology clinical trials
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Subscribe To Our Newsletter & Stay Updated
